World's Best Scientists 2026 revealed!
Herbert Hurwitz

Herbert Hurwitz

D-Index & Metrics

Medicine

D-Index
86
Citations
45286
World Ranking
13860
National Ranking
7036

Herbert Hurwitz publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Herbert Hurwitz sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 444 publications — 48th percentile

48% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Herbert Hurwitz D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Herbert Hurwitz sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 86 D-Index — 31st percentile

31% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Herbert Hurwitz is affiliated with Duke University in the United States and has contributed extensively to the field of medicine, with a primary focus on oncology. Their scholarly work spans numerous subfields, including oncology, pulmonary and respiratory medicine, cancer research, pathology and forensic medicine, and hepatology.

Their research topics cover various aspects of cancer treatment and study, especially colorectal and gastric cancers. Key topic areas include colorectal cancer treatments and studies, gastric cancer management and outcomes, cancer treatment and pharmacology, cancer genomics and diagnostics, genetic factors in colorectal cancer, hepatocellular carcinoma treatment and prognosis, and pancreatic and hepatic oncology research.

Frequent publication venues for Herbert Hurwitz include the Journal of Clinical Oncology, UNC Libraries, European Journal of Cancer, Clinical Cancer Research, and Cancers. Their publication record shows a particular concentration in leading oncology journals.

Notable recent papers authored or co-authored by Herbert Hurwitz are:

  • Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlook, 2020, Cancer Treatment Reviews
  • Individual Patient Data Meta-Analysis of FOLFOXIRI Plus Bevacizumab Versus Doublets Plus Bevacizumab as Initial Therapy of Unresectable Metastatic Colorectal Cancer, 2020, Journal of Clinical Oncology
  • Assessment of Capecitabine and Bevacizumab With or Without Atezolizumab for the Treatment of Refractory Metastatic Colorectal Cancer, 2022, JAMA Network Open
  • Predictive Blood-Based Biomarkers in Patients with Epithelial Ovarian Cancer Treated with Carboplatin and Paclitaxel with or without Bevacizumab: Results from GOG-0218, 2020, Clinical Cancer Research
  • Disease Monitoring Using Post-induction Circulating Tumor DNA Analysis Following First-Line Therapy in Patients with Metastatic Colorectal Cancer, 2020, Clinical Cancer Research

Herbert Hurwitz has collaborated frequently with several researchers including Qian Shi, Aimery de Gramont, Benoist Chibaudel, John Zalcberg, and Leonard B. Saltz, highlighting a network of professional associations within oncology research.

Best Publications

  • BEVACIZUMAB PLUS IRINOTECAN, FLUOROURACIL, AND LEUCOVORIN FOR METASTATIC COLORECTAL CANCER

    Herbert Hurwitz;Louis Fehrenbacher;William Novotny;Thomas Cartwright

  • Phase II, Randomized Trial Comparing Bevacizumab Plus Fluorouracil (FU)/Leucovorin (LV) With FU/LV Alone in Patients With Metastatic Colorectal Cancer

    Fairooz Kabbinavar;Herbert I. Hurwitz;Louis Fehrenbacher;Neal J. Meropol

  • Arterial Thromboembolic Events in Patients with Metastatic Carcinoma Treated with Chemotherapy and Bevacizumab

    Frank A. Scappaticci;Jamey R. Skillings;Scott N. Holden;Hans Peter Gerber

  • Gemcitabine Plus Bevacizumab Compared With Gemcitabine Plus Placebo in Patients With Advanced Pancreatic Cancer: Phase III Trial of the Cancer and Leukemia Group B (CALGB 80303)

    Hedy Lee Kindler;Donna Niedzwiecki;Donna Hollis;Susan Sutherland

  • Bevacizumab in Combination With Fluorouracil and Leucovorin: An Active Regimen for First-Line Metastatic Colorectal Cancer

    Herbert I. Hurwitz;Louis Fehrenbacher;John D. Hainsworth;William Heim

  • Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer

    Fairooz F. Kabbinavar;Julie Hambleton;Robert D. Mass;Herbert I. Hurwitz

  • Phase I Safety, Pharmacokinetics, and Clinical Activity Study of Lapatinib (GW572016), a Reversible Dual Inhibitor of Epidermal Growth Factor Receptor Tyrosine Kinases, in Heavily Pretreated Patients With Metastatic Carcinomas

    Howard A. Burris;Herbert I. Hurwitz;E. Claire Dees;Afshin Dowlati

  • Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlook.

    Josep Garcia;Herbert I. Hurwitz;Alan B. Sandler;David Miles

  • Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab

    Frank A. Scappaticci;Louis Fehrenbacher;Thomas Cartwright;John D. Hainsworth

  • Phase I Trial of Pazopanib in Patients with Advanced Cancer

    Herbert I. Hurwitz;Afshin Dowlati;Shermini Saini;Shawna Savage

  • Impact of Vascular Endothelial Growth Factor-A Expression, Thrombospondin-2 Expression, and Microvessel Density on the Treatment Effect of Bevacizumab in Metastatic Colorectal Cancer

    Adrian M. Jubb;Herbert I. Hurwitz;Wei Bai;Eric B. Holmgren

  • Primary Tumor Location as a Prognostic Factor in Metastatic Colorectal Cancer

    Fotios Loupakis;Dongyun Yang;Linda Yau;Shibao Feng

  • Lower frequency of peritoneal carcinomatosis in patients with pancreatic cancer diagnosed by EUS-guided FNA vs. percutaneous FNA

    Carlos Micames;Paul S Jowell;Rebekah White;Erik Paulson

  • Study of the Biologic Effects of Lapatinib, a Reversible Inhibitor of ErbB1 and ErbB2 Tyrosine Kinases, on Tumor Growth and Survival Pathways in Patients With Advanced Malignancies

    Neil L. Spector;Wenle Xia;Howard Burris;Herbert Hurwitz

  • Targeted therapy for advanced solid tumors on the basis of molecular profiles: Results from mypathway, an open-label, phase IIA multiple basket study

    John D. Hainsworth;Funda Meric-Bernstam;Charles Swanton;Herbert Hurwitz

  • Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study.

    Funda Meric-Bernstam;Herbert Hurwitz;Kanwal Pratap Singh Raghav;Robert R McWilliams

  • Association of k-ras, b-raf, and p53 Status With the Treatment Effect of Bevacizumab

    William L. Ince;Adrian M. Jubb;Scott N. Holden;Eric B. Holmgren

  • Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors

    S. N. Holden;S. G. Eckhardt;R. Basser;R. de Boer

  • A double-blind, placebo-controlled, randomized phase III trial of gemcitabine (G) plus bevacizumab (B) versus gemcitabine plus placebo (P) in patients (pts) with advanced pancreatic cancer (PC): A preliminary analysis of Cancer and Leukemia Group B (CALGB

    H. L. Kindler;D. Niedzwiecki;D. Hollis;E. Oraefo

  • The Clinical Benefit of Bevacizumab in Metastatic Colorectal Cancer Is Independent of K-ras Mutation Status: Analysis of a Phase III Study of Bevacizumab with Chemotherapy in Previously Untreated Metastatic Colorectal Cancer

    Herbert I. Hurwitz;Jing Yi;William Ince;William F. Novotny

Frequent Co-Authors

Johanna C. Bendell
Johanna C. Bendell Sarah Cannon Research Institute
Michael A. Morse
Michael A. Morse Duke University
Gerard C. Blobe
Gerard C. Blobe Duke University
Donna Niedzwiecki
Donna Niedzwiecki Duke University
Leonard Saltz
Leonard Saltz Memorial Sloan Kettering Cancer Center
Theodore N. Pappas
Theodore N. Pappas Duke University
Richard M. Goldberg
Richard M. Goldberg West Virginia University
John D. Hainsworth
John D. Hainsworth Sarah Cannon Research Institute
Christopher G. Willett
Christopher G. Willett Duke University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those considering additional career options in medicine beyond the traditional MD route, there are several flexible online degrees available. Many students and professionals are looking to expand their qualifications in fields like management, nursing, and pharmacy—all of which are essential to healthcare.

An important factor to consider when exploring these educational opportunities is cost. Comparing healthcare administration degree cost can help you find programs that match your budget and career goals. If you're interested in leadership or administrative roles, there are a number of affordable mha online programs designed to fit busy schedules.

Nursing professionals can take the next step with the cheapest online dnp programs, making advanced practice and leadership roles accessible without the burden of high tuition. In the field of pharmacology, students can pursue a PharmD from home by researching options for pharmacy school online.

These affordable online programs open new career pathways in healthcare while helping you manage both time and finances effectively.

Best Scientists Citing Herbert Hurwitz

Trending Scientists

Recently Published Articles